JPWO2022206929A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022206929A5 JPWO2022206929A5 JP2023560644A JP2023560644A JPWO2022206929A5 JP WO2022206929 A5 JPWO2022206929 A5 JP WO2022206929A5 JP 2023560644 A JP2023560644 A JP 2023560644A JP 2023560644 A JP2023560644 A JP 2023560644A JP WO2022206929 A5 JPWO2022206929 A5 JP WO2022206929A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharma
- pharmaceutical composition
- solvate
- structure represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 239000013078 crystal Substances 0.000 claims 6
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 102220004843 rs397516975 Human genes 0.000 claims 3
- SADXACCFNXBCFY-IYNHSRRRSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\[C@@H]3N(CCC3)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 SADXACCFNXBCFY-IYNHSRRRSA-N 0.000 claims 2
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 claims 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 229950008835 neratinib Drugs 0.000 claims 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 2
- 229940075576 pyrotinib Drugs 0.000 claims 2
- 229950003463 tucatinib Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229940117913 acrylamide Drugs 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110358192 | 2021-04-01 | ||
| CN202110358192.3 | 2021-04-01 | ||
| PCT/CN2022/084650 WO2022206929A1 (zh) | 2021-04-01 | 2022-03-31 | 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514098A JP2024514098A (ja) | 2024-03-28 |
| JP2024514098A5 JP2024514098A5 (https=) | 2024-04-11 |
| JPWO2022206929A5 true JPWO2022206929A5 (https=) | 2024-04-11 |
Family
ID=83458071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560644A Pending JP2024514098A (ja) | 2021-04-01 | 2022-03-31 | ＥｒｂＢ２突然変異体を標的とする阻害薬の調製における化合物の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240197737A1 (https=) |
| EP (1) | EP4316491A4 (https=) |
| JP (1) | JP2024514098A (https=) |
| CN (1) | CN115192580A (https=) |
| WO (1) | WO2022206929A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN116606289B (zh) * | 2022-02-17 | 2026-02-24 | 上海医药集团股份有限公司 | 一种含氮杂环化合物的晶型、制备方法及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007095038A2 (en) * | 2006-02-09 | 2007-08-23 | Novartis Ag | Mutations and polymorphisms of erbb2 |
| JP6791979B2 (ja) | 2016-03-01 | 2020-11-25 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用 |
| EP3677583A4 (en) * | 2017-09-01 | 2021-07-21 | Shanghai Pharmaceuticals Holding Co., Ltd. | NITROGENOUS HETEROCYCLIC COMPOUND, METHOD OF PREPARATION, INTERMEDIATE, COMPOSITION AND APPLICATION |
| EP3946293A4 (en) * | 2019-03-29 | 2023-05-03 | Board of Regents, The University of Texas System | COMPOUNDS WITH ANTITUMORIC ACTIVITIES AGAINST CANCER CELLS WITH EGFR OR HER2 EXON 20 INSERTATIONS |
-
2022
- 2022-03-31 JP JP2023560644A patent/JP2024514098A/ja active Pending
- 2022-03-31 US US18/284,162 patent/US20240197737A1/en active Pending
- 2022-03-31 EP EP22779109.2A patent/EP4316491A4/en active Pending
- 2022-03-31 WO PCT/CN2022/084650 patent/WO2022206929A1/zh not_active Ceased
- 2022-03-31 CN CN202210356800.1A patent/CN115192580A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7530391B2 (ja) | がんの治療のためのｅｇｆｒ阻害剤 | |
| JP7530390B2 (ja) | 新規ｅｇｆｒ阻害剤 | |
| ES2892954T3 (es) | Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos | |
| US12083118B2 (en) | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same | |
| ES2539518T3 (es) | Inhibidores de proteínas quinasas | |
| CN105228620B (zh) | 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物 | |
| JP7328323B2 (ja) | ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物 | |
| JP2024161461A (ja) | がんの治療または予防用医薬 | |
| WO2010031265A1 (zh) | 用于治疗增生性疾病的药物组合物 | |
| JP6795518B2 (ja) | キナーゼを阻害する組成物及び方法 | |
| CN107454898B (zh) | 生长素释放肽o-酰基转移酶抑制剂 | |
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| CA2474874A1 (en) | Anticholinergic agents, method for producing the same and use thereof as medicaments | |
| WO2014079232A1 (zh) | 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用 | |
| WO2012155806A1 (zh) | 4-氨基喹唑啉衍生物及其应用 | |
| WO2016023217A1 (zh) | 喹唑啉衍生物、其制备方法、药物组合物和应用 | |
| TW202313050A (zh) | 組合療法 | |
| US20250333387A1 (en) | Crystalline chloro-n-(4-(morpholinomethyl)phenyl)benzamide and crystalline hydrochloride salt | |
| CN103648500A (zh) | 双功能酶制钳型分子的方法和用途 | |
| WO2011131135A1 (zh) | 芳杂（烷基）氨基二硫代甲酸酯类化合物、其制备方法和应用 | |
| JP2009500409A (ja) | 痛みを処置するためのα２アドレナリン作動剤 | |
| JP2020531574A (ja) | 化合物、その医薬組成物及びその使用及び応用 | |
| JP2023145544A (ja) | 線維症を処置するための化合物および組成物 | |
| JPWO2022206929A5 (https=) | ||
| JPWO2022254371A5 (https=) |